Significant biosimilar activities this week include:

  • 22 Oct 20: Ph III clinical trials of FYB202 (proposed ustekinumab biosimilar developed by Formycon and Bioeq) commenced recruiting in Poland
     

  • 26 Oct 20: Samsung Bioepis announced results from two post-mar...

September 14, 2020

Significant biosimilar activities this week include:

  • 08 Sep 20: The Centre for Biosimilars reports a new study published in Diabetes Spectrum suggests FDA biosimilar naming requirements and switching restrictions cause patients to perceive biosimilars as less simila...

Significant biosimilar activities this week include:

  • On 14 April 2020, Mylan and Biocon launched Fulphila® (pegfilgrastim) in Australia. Fulphila® is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropeni...

Significant biosimilar activities this week include:

  • On 09 March 2020, the FDA and FTC held a public workshop to further their efforts in creating a better biosimilar landscape in the US. The Centre for Biosimilars reported that topics discussed at the conference in...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags